Business Context and Reporting Period
This Form 8-K is a current report filed by ADVENTRX Pharmaceuticals, Inc. (not Savara Inc.) on August 24, 2009. The filing discloses the resignation of a director and the subsequent entry into a material definitive agreement.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific compensatory arrangement:
- Consulting Fee Rate: $250 per hour.
- Fee Cap: $25,000 total.
- Minimum Monthly Obligation: Starting September 2009, the company must either request or pay for a minimum of four hours of service ($1,000) per calendar month.
- Agreement Term: Effective immediately prior to resignation through August 31, 2010.
Material Changes
The primary material change reported is the resignation of Mark N. K. Bagnall from the Board of Directors, effective immediately on August 24, 2009. Concurrent with this departure, the company entered into a Consulting Agreement with Mr. Bagnall.
Outlook, Risks, and Management Commentary
Management Commentary: The filing explicitly states that Mr. Bagnall's resignation was not due to any disagreement with the company regarding its operations, policies, or practices.
Risks and Contingencies: No specific financial risks or contingencies are detailed in this report beyond the contractual obligation to pay the consulting fees as outlined in the agreement.
Investor Verification Checklist
- Verify the identity of the registrant (ADVENTRX Pharmaceuticals, Inc.) versus the requested company name (Savara Inc.).
- Confirm the terms of the Consulting Agreement (Exhibit 10.1) regarding the $25,000 cap and minimum monthly payments.
- Review the composition of the Board of Directors following Mr. Bagnall's immediate resignation.
- Check for any subsequent filings regarding the status of the consulting relationship or further board changes.